Are You Suffering from urinary incontinence?

The last week of June each year is the World Continence Week. Studies have shown that urinary incontinence has become one of the world‘s five major diseases after cancer, diabetes, hypertension and osteoporosis. About 20% of the world‘s people are suffering from urinary incontinence. With the aging of the population, urinary incontinence patients will be more and more.
If accompanied by frequent urination,urgent urination and Nocturia, patients may suffer from overactive bladder (OAB).
Mirabegron is a first-in-class β3-adrenoceptor agonist licensed for the treatment of OAB. It was developed by Astellas Pharma Inc., and approved by FDA in 2012. Mirabegron quickly occupied the market of OAB in the United States and Japan after marketing. It was approved by NMPA in September 2017 and traded in Betmiga, which has changed the traditional pattern of Chinese OAB market dominated by antimuscarinics.
In order to facilitate the R&D of pharmaceutical companies and CRO, we launched part of spot impurity reference substances of Mirabegron during the World Continence Week. For more information, please call 0755-26050679 or follow our official website: http://www.ex-biotech.com/.